Table 3 Differentially expressed genes repeatedly (≥2) identified in the three comparisons (C vs. P, R vs. NR, and Pre vs. Post)

From: Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis

Gene symbol

Full gene name

Comparison

FCa

P

Corrected P

Comparison

FCa

P

Corrected P

Responsiveness to SSRIs

 FCRL6

Fc receptor-like 6

R vs. NR

1.48

3.54 × 10−2

4.78 × 10−1

Pre vs. Post

1.21

1.72 × 10−3

6.94 × 10−2

 HSPH1

Heat shock 105 kDa/110 kDa protein 1

R vs. NR

1.41

2.36 × 10−2

4.45 × 10−1

C vs. P

1.32

1.24 × 10−2

2.82 × 10−1

 IGKC

Immunoglobulin kappa constant

R vs. NR

1.64

6.30 × 10−3

3.95 × 10−1

C vs. P

0.76

4.29 × 10−2

4.25 × 10−1

 BTNL8

Butyrophilin-like 8

Pre vs. Post

0.81

5.54 × 10−3

1.06 × 10−1

C vs. P

1.59

1.63 × 10−3

1.33 × 10−1

 KATNBL1

Katanin p80 subunit B-like 1

Pre vs. Post

0.83

1.02 × 10−3

6.12 × 10−2

C vs. P

1.38

2.02 × 10−3

1.41 × 10−1

 LYVE1

Lymphatic vessel endothelial hyaluronan receptor 1

Pre vs. Post

0.83

9.09 × 10−4

5.95 × 10−2

C vs. P

1.28

3.56 × 10−2

3.97 × 10−1

 MIR15A

MicroRNA 15a

Pre vs. Post

0.81

2.82 × 10−2

2.05 × 10−1

C vs. P

1.50

1.36 × 10−2

2.91 × 10−1

 PTCH2

Patched 2

Pre vs. Post

1.21

4.57 × 10−3

9.84 × 10−2

C vs. P

0.60

7.97 × 10−4

1.04 × 10−1

 SCARNA17

Small Cajal body-specific RNA 17

Pre vs. Post

1.21

1.08 × 10−3

6.15 × 10−2

C vs. P

0.78

1.89 × 10−2

3.23 × 10−1

Responsiveness to mirtazapine

 GPAT3

Glycerol-3-phosphate acyltransferase 3

R vs. NR

1.39

4.55 × 10−2

5.44 × 10−1

C vs. P

1.32

1.86 × 10−2

3.20 × 10−1

 ANKRD55

Ankyrin repeat domain 55

R vs. NR

1.33

2.08 × 10−2

5.23 × 10−1

C vs. P

1.20

4.12 × 10−2

4.19 × 10−1

 BRCA1

Breast cancer 1

R vs. NR

1.26

3.36 × 10−2

5.33 × 10−1

C vs. P

1.21

1.06 × 10−2

2.63 × 10−1

 C11orf54

Chromosome 11 open reading frame 54

R vs. NR

1.22

4.65 × 10−2

5.48 × 10−1

C vs. P

1.30

2.98 × 10−4

7.51 × 10−2

 C20orf197

Chromosome 20 open reading frame 197

R vs. NR

1.22

2.16 × 10−2

5.24 × 10−1

C vs. P

1.24

5.21 × 10−4

8.60 × 10−2

 CC2D2B

Coiled-coil and C2 domain containing 2B

R vs. NR

1.27

4.68 × 10−2

5.48 × 10−1

C vs. P

1.26

3.14 × 10−2

3.80 × 10−1

 CEP63

Centrosomal protein 63 kDa

R vs. NR

1.37

4.36 × 10−2

5.43 × 10−1

C vs. P

1.27

2.93 × 10−2

3.72 × 10−1

 DUSP18

Dual specificity phosphatase 18

R vs. NR

1.22

3.46 × 10−2

5.34 × 10−1

C vs. P

1.28

3.78 × 10−4

8.15 × 10−2

 FRMD4B

FERM domain containing 4B

R vs. NR

0.76

2.98 × 10−2

5.26 × 10−1

C vs. P

0.83

3.58 × 10−2

3.98 × 10−1

 GPSM2

G-protein signaling modulator 2

R vs. NR

1.34

2.58 × 10−2

5.26 × 10−1

C vs. P

1.21

4.06 × 10−2

4.18 × 10−1

 IGF2BP2

Insulin-like growth factor 2 mRNA binding protein 2

R vs. NR

0.79

2.77 × 10−2

5.26 × 10−1

C vs. P

0.82

7.66 × 10−3

2.30 × 10−1

 KIAA0753

KIAA0753

R vs. NR

1.20

4.46 × 10−2

5.43 × 10−1

C vs. P

1.30

9.02 × 10−5

5.20 × 10−2

 LIMS1

LIM and senescent cell antigen-like domains 1

R vs. NR

0.73

2.18 × 10−2

5.24 × 10−1

C vs. P

0.82

4.14 × 10−2

4.21 × 10−1

 LOC100132686

Uncharacterized LOC100132686

R vs. NR

1.22

7.49 × 10−3

5.05 × 10−1

C vs. P

1.26

5.83 × 10−5

4.84 × 10−2

 MPHOSPH8

M-phase phosphoprotein 8

R vs. NR

1.22

1.37 × 10−2

5.07 × 10−1

C vs. P

1.26

1.78 × 10−4

5.99 × 10−2

 PLXND1

Plexin D1

R vs. NR

0.78

2.30 × 10−2

5.26 × 10−1

C vs. P

0.83

1.21 × 10−2

2.81 × 10−1

 PPP1R21

Protein phosphatase 1 regulatory subunit 21

R vs. NR

1.20

3.36 × 10−2

5.33 × 10−1

C vs. P

1.28

9.75 × 10−5

5.20 × 10−2

 SLA2

Src-like-adaptor 2

R vs. NR

0.74

3.70 × 10−2

5.37 × 10−1

C vs. P

0.80

2.40 × 10−2

3.48 × 10−1

 TOPORS

Topoisomerase I binding, arginine/serine-rich, E3 ubiquitin protein ligase

R vs. NR

1.30

4.77 × 10−2

5.49 × 10−1

C vs. P

1.23

2.76 × 10−2

3.65 × 10−1

 TSPAN33

Tetraspanin 33

R vs. NR

0.71

2.07 × 10−2

5.22 × 10−1

C vs. P

0.75

9.26 × 10−3

2.48 × 10−1

 ZNF844

Zinc finger protein 844

R vs. NR

1.28

4.24 × 10−2

5.41 × 10−1

C vs. P

1.21

3.51 × 10−2

3.96 × 10−1

  1. C vs. P controls vs. patients, R vs. NR responders vs. nonresponders, Pre vs. Post at baseline vs. at 6 weeks after antidepressant treatment, FC fold change, SSRIs selective serotonin reuptake inhibitors
  2. *aFold changes in patients compared to controls (P/C), at baseline in nonresponders compared to responders (NR/R), and at 6 weeks of antidepressant treatment compared to baseline (Post/Pre)
Back to article page